RGA
NKTR icon

Red Granite Advisors’s Nektar Therapeutics NKTR Stock Holding History

Red Granite Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$116K Sell
741
-107
-13% -$19.8K 0.03% 61
2013
Q2 		$147K Buy
+848
New +$130K 0.04% 57

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Red Granite Advisors's NKTR Position: Q3 2013 in Review

Red Granite Advisors reduced its Nektar Therapeutics (NKTR) stake by 13% in Q3 2013, selling an estimated $19.8K and leaving 741 shares worth $116K. The position accounts for 0.03% of the portfolio, ranked #61.

Red Granite Advisors first reported a position in NKTR in Q2 2013 and has held it in 2 quarters since. The position peaked at $147K in Q2 2013. 142 funds tracked by Wall St. Rank hold NKTR as of Q3 2013.

  • Red Granite Advisors held 741 shares of Nektar Therapeutics worth $116K as of Q3 2013.
  • Red Granite Advisors sold 107 Nektar Therapeutics shares in Q3 2013, an estimated $19.8K.
  • Nektar Therapeutics made up 0.03% of Red Granite Advisors's portfolio in Q3 2013, its #61 holding.
  • Red Granite Advisors first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 2 quarters since.
  • Red Granite Advisors's Nektar Therapeutics position peaked at $147K in Q2 2013.
  • 142 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2013.

Based on Red Granite Advisors's 13F filing for Q3 2013, filed 6 Nov 2013.